Octreotide Conjugates for Tumor Targeting and Imaging.

Area of Science:

• Oncology
• Pharmacology
• Bioconjugation

Background:

• Tumor targeting enhances the efficacy and safety of therapeutic agents.
• Somatostatin receptors (SSTRs) are overexpressed in neuroendocrine tumors (NETs).
• Octreotide, a somatostatin analog, is a known SSTR-targeting agent.

Purpose of the Study:

• To develop and evaluate octreotide-conjugated agents for targeted delivery to SSTR-expressing tumors.
• To investigate the role of linker chemistry in the stability and efficacy of these conjugates.
• To assess the in vitro and in vivo tumor-targeting capabilities of novel octreotide conjugates.

Main Methods:

• Conjugation of the cytotoxic agent cryptophycin to octreotide via a protease-cleavable Val-Cit linker and self-immolative moieties.
• In vitro assessment of conjugate stability and biological activity.
• In vivo evaluation of tumor targeting using an infrared dye (Cy5.5) conjugate in xenograft models.

Main Results:

• The self-immolative moiety significantly influenced the stability of the octreotide conjugates.
• Octreotide-Cy5.5 conjugates demonstrated efficient and selective internalization in SSTR2-overexpressing cells.
• Conjugates showed prolonged accumulation in tumor xenografts in vivo.

Conclusions:

• Octreotide serves as an effective delivery vehicle for targeted cancer therapy.
• The linker and self-immolative group are critical for optimizing conjugate performance.
• This approach holds promise for improving the therapeutic index of cytotoxic agents in NETs.